Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL)

類似資料

• Promising results of an anti-CCR4 antibody, KW-0761, for relapsed Adult T-Cell Leukemia-Lymphoma (ATL)
  著者:: Utsunomiya, Atae, 等
  出版事項: (2011)
• Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma
  著者:: Phillips, Adrienne A., 等
  出版事項: (2019)
• Humanized anti CCR4 antibody KW0761 targets HTLV-1 infected CD4+ CCR4+ and CD8+CCR4+ T cells to treat HAM/TSP
  著者:: Yamano, Yoshihisa, 等
  出版事項: (2015)
• Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma
  著者:: Duvic, Madeleine, 等
  出版事項: (2015)
• Can we cure ATL: new drugs and targeting ATL stem cells
  著者:: Hermine, Olivier
  出版事項: (2014)